bioRxivPhysiology
Comparative Analysis of Right Ventricular Metabolic Reprogramming in Pre-clinical Rat Models of Severe Pulmonary Hypertension-induced Right Ventricular Failure
Abstract
BackgroundPulmonary hypertension (PH) leads to right ventricular (RV) hypertrophy and failure (RVF). The precise mechanisms of the metabolic basis of maladaptive PH-induced RVF (PH-RVF) are yet to be fully elucidated. Here we performed a comparative analysis of RV-metabolic reprogramming in MCT and Su/Hx rat models of severe PH-RVF using targeted metabolomics and multi-omics. MethodsMale Sprague Dawley rats (250-300gm; n=15) were used. Rats received subcutaneous monocrotaline (60mg/kg; MCT; n=5) and followed for [~]30-days or Sugen (20mg/kg; Su/Hx; n=5) followed by hypoxia (10%O2; 3-weeks) and normoxia (2-weeks). Controls received saline (Control; n=5). Serial echocardiography was performed to assess cardiopulmonary hemodynamics. Terminal RV-catheterization was performed to assess PH. Targeted metabolomics was performed on RV tissue using UPLC-MS. RV multi-omics analysis was performed integrating metabolomic and transcriptomic datasets using Joint Pathway Analysis (JPA). ResultsMCT and Su/Hx rats developed severe PH, RV-hypertrophy and decompensated RVF. Targeted metabolomics of RV of MCT and Su/Hx rats detected 126 and 125 metabolites respectively. There were 28 and 24 metabolites significantly altered in RV of MCT and Su/Hx rats, respectively, including 11 common metabolites. Common significantly upregulated metabolites included aspartate and GSH, whereas downregulated metabolites included phosphate, -ketoglutarate, inositol, glutamine, 5-Oxoproline, hexose phosphate, creatine, pantothenic acid and acetylcarnitine. JPA highlighted common genes and metabolites from key pathways such as glycolysis, fatty acid metabolism, oxidative phosphorylation, TCA cycle etc. ConclusionsComparative analysis of metabolic reprogramming of RV from MCT and Su/Hx rats reveals common and distinct metabolic signatures which may serve as RV-specific novel therapeutic targets for PH-RVF.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Reduction in activity and abundance of mitochondrial electron transport chain supercomplexes in pulmonary hypertension-induced right ventricular dysfunction
W. Ma, P. Zhang, … R. T. Clements·bioRxiv·Mar 8, 2024
- Reducing Reactive Lipids Improves Cardiac Metabolic and Diastolic Function in Pulmonary Hypertension Models
James D. West, Christy Moore, … Anna R. Hemnes·bioRxiv·Oct 10, 2025
- Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension
Ivor Clinton, Julie C. Coursen, … PVDOMICS Study Group·bioRxiv·Jun 22, 2026
- RV-specific Targeting of Snai1 Rescues Pulmonary Hypertension-induced Right Ventricular Failure by Inhibiting EndMT and Fibrosis via LOXL2 Mediated Mechanism
Somanshu Banerjee, Varina R. Clark, … Soban Umar·bioRxiv·Apr 30, 2024
- Proteomic and Metabolomic Profiling Nominates Druggable Targets and Biomarkers forPulmonary Arterial Hypertension-Associated Myopathy and Exercise Intolerance
Phablo Abreu, Ryan A. Moon, … Kurt W. Prins·bioRxiv·Mar 27, 2025
- Work and oxygen consumption of isolated right ventricular papillary muscle in experimental pulmonary hypertension
W. J. van der Laarse, S. J. P. Bogaards, … D. van Groen·bioRxiv·Dec 30, 2021